All In Biotech

Drug Trial Radar · NCT07890298

A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant

An Open-Label, Single-Arm, Exploratory Study to Evaluate Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in Participants With Acute Ischemic Stroke (AIS)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 31, 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Lumosa Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 88 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)

Conditions

  • Acute Ischemic Stroke

Interventions

  • LT3001 Drug ProductDrug

    Administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of successful recanalization at 24 hours after the 1st IP. Successful recanalization is defined as any improvement in Arterial Occlusive Lesion (AOL) score.Time frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taichung Medical University, Taichung

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.